Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
TOP STORIES — Diabetes News and Research
Adiposity and Fat Distribution Impact on Hypertension, Cholesterol, and Diabetes
Tirzepatide a Potential Drug for Weight Loss
Benefits for Patients with Type 1 Diabetes Using the New Omnipod® 5
MOST POPULAR ARTICLES OF THE MONTH
#2 FDA Approves 1st AI Insulin Pen Cap, Making Insulin Dosing Simple
#3 A Potential New Oral Medication for Type 1 Diabetes and How It May Affect Exercise
Letter from the Editor
Brenda Oppong, PharmD Candidate, LECOM School of Pharmacy, has been doing some research on insulin delivery systems and the technology behind them. She had reviewed the T:Slim and Medtronic automated systems, with their ability to predict future glucose levels and adjust insulin delivery up or down based on CGM information. Although these devices are very convenient, many patients have been hesitant to use the devices, as they felt they did not want tubing coming out of their body.
The Omnipod system from Insulet does not have external tubing and is a more discreet device for many of our patients. In the past Omnipod has suffered because it lacked the CGM connectivity and real time management.
Omnipod has just introduced the Omnipod® 5, and this device has all the bells and whistles of the tubed pumps. This means that your patients can take advantage of the AI that is in the device to manage their glucose levels, and allow the device to predict future problems and correct them.
I think that you will find that the Omnipod® 5 will make a difference in many lives.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
TOP STORIES — Diabetes News and Research
Central adiposity shows varying effects on blood pressure, LDL cholesterol, and glycemic profile.
Novel dual GIP and GLP-1 receptor agonist showed promising results for both reduction in A1C and weight loss.
How safe and effective is the first commercial configuration of a tubeless automated insulin delivery system in children and adults with type 1 diabetes?